Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CTSS | P25774 | 8/20 | 0.48 |
| ▸ | CTSL | P07711 | 7/20 | 0.48 |
| ▸ | CTSB | P07858 | 7/20 | 0.48 |
| ▸ | CTSK | P43235 | 7/20 | 0.42 |
| ▸ | ERAP2 | Q6P179 | 2/20 | 0.40 |
| ▸ | IL1RN | P18510 | 1/20 | 0.40 |
| ▸ | ERAP1 | Q9NZ08 | 1/20 | 0.40 |
| ▸ | LNPEP | Q9UIQ6 | 1/20 | 0.38 |
| ▸ | ECE1 | P42892 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27964731 | 1.00 | CTSS (0.48) | CTSSCTSLCTSBCTSKERAP2 | |
| SCHEMBL27965030 | 0.86 | ECE1 (0.40) | CTSSCTSLCTSBCTSKECE1 | |
| SCHEMBL1850933 | 0.86 | ECE1 (0.40) | CTSSCTSLCTSBCTSKECE1 | |
| SCHEMBL1838673 | 0.80 | CTSS (0.48) | CTSSCTSLCTSBCTSKERAP2 | |
| SCHEMBL27965014 | 0.80 | CTSS (0.62) | CTSSCTSLCTSBCTSK | |
| SCHEMBL1840160 | 0.80 | CTSS (0.62) | CTSSCTSLCTSBCTSK | |
| SCHEMBL1839814 | 0.80 | CTSS (0.47) | CTSSCTSLCTSBCTSK | |
| SCHEMBL28812052 | 0.80 | CTSS (0.47) | CTSSCTSLCTSBCTSK | |
| SCHEMBL27965067 | 0.79 | CTSS (0.63) | CTSSCTSLCTSBCTSKECE1 | |
| SCHEMBL1855255 | 0.79 | CTSS (0.63) | CTSSCTSLCTSBCTSKECE1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8957205-B2 | Cycloalkane carboxamide derivatives and production process of same | SEIKAGAKU CORPORATION (JP) | 2015-02-17 | — | — | US | disclosed |
| US-8829209-B2 | Cycloalkylcarbonylamino acid ester derivative and process for producing the same | SEIKAGAKU CORPORATION (JP) | 2014-09-09 | — | — | US | disclosed |
| CN-101370773-B | Cycloalkanecarboxamide derivative and method for producing same | SEIKAGAKU KOGYO CO LTD | 2014-04-09 | — | — | CN | disclosed |
| EP-2036920-B1 | CYCLOALKYLCARBONYLAMINO ACID ESTER DERIVATIVE AND PROCESS FOR PRODUCING THE SAME | SEIKAGAKU KOGYO CO LTD (JP) | 2011-05-18 | — | — | EP | disclosed |
| US-20090156805-A1 | Cycloalkane Carboxamide Derivatives and Production Process of Same | SEIKAGAKU CORPORATION (JP) | 2009-06-18 | — | — | US | disclosed |
| US-20090137799-A1 | Cycloalkylcarbonylamino Acid Ester Derivative and Process for Producing The Same | SEIKAGAKU CORPORATION (JP) | 2009-05-28 | — | — | US | disclosed |
| EP-2036920-A1 | CYCLOALKYLCARBONYLAMINO ACID ESTER DERIVATIVE AND PROCESS FOR PRODUCING THE SAME | SEIKAGAKU CORPORATION (JP) | 2009-03-18 | — | — | EP | disclosed |
| EP-1972615-A1 | CYCLOALKANECARBOXAMIDE DERIVATIVE AND METHOD FOR PRODUCING SAME | SEIKAGAKU CORPORATION (JP) | 2008-09-24 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090156805-A1 | Cycloalkane Carboxamide Derivatives and Production Process of Same | CTSK, CTSS, CTSB | CTSS 2/4885CTSL 13/4885CTSB 3/4885 |
| US-20090137799-A1 | Cycloalkylcarbonylamino Acid Ester Derivative and Process for Producing The Same | CTSK, CTSS, CTSE | CTSS 2/4885CTSL 9/4885CTSB 6/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.